Aljian Capital Management LLC Invests $479,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Aljian Capital Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 5,715 shares of the biopharmaceutical company's stock, valued at approximately $479,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. lifted its holdings in Gilead Sciences by 198.3% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 238 shares during the period. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares in the last quarter. Cedar Wealth Management LLC grew its stake in Gilead Sciences by 51.6% during the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the second quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,947 shares of company stock valued at $4,968,674 over the last quarter. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 0.1 %

Shares of NASDAQ:GILD traded up $0.06 during trading hours on Monday, hitting $88.46. 9,099,602 shares of the company's stock traded hands, compared to its average volume of 7,110,947. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 0.82. The business has a fifty day moving average price of $86.87 and a 200-day moving average price of $76.27. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The firm has a market capitalization of $110.24 billion, a P/E ratio of 982.89, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 4.38 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 3,422.22%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. Wolfe Research began coverage on Gilead Sciences in a report on Friday. They set an "outperform" rating and a $110.00 price target on the stock. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an "outperform" rating and a $105.00 target price on the stock. Robert W. Baird lifted their price target on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research note on Thursday, November 7th. Barclays increased their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald boosted their target price on Gilead Sciences from $70.00 to $80.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.